R-DXd + Bevacizumab for Ovarian Cancer

This trial explores new ways to treat ovarian cancer by testing a combination of treatments. It compares the use of a new drug, Raludotatug Deruxtecan (R-DXd), with or without bevacizumab, against standard care, which may include bevacizumab or just observation. The main goal is to determine if this new approach can help patients live longer without their cancer worsening. This trial may suit those diagnosed with advanced ovarian cancer who have completed initial chemotherapy and undergone surgery to remove cancer. As a Phase 3 trial, it represents the final step before FDA approval, offering patients a chance to access potentially groundbreaking treatment.

The trial information does not specify if you need to stop taking your current medications. However, if you have HIV, you must have it well-controlled on antiretroviral therapy. It's best to discuss your specific medications with the trial team.

Research has shown that raludotatug deruxtecan (R-DXd) holds promise in treating cancers. In earlier studies, patients taking R-DXd experienced some side effects, with nausea (feeling sick), anemia (low red blood cell count), and weakness being the most common. About 69%, 57%, and 47% of patients reported these side effects, respectively.

Researchers are excited about Raludotatug Deruxtecan (R-DXd) for ovarian cancer because it offers a novel approach compared to current treatments. Unlike standard options like bevacizumab, which primarily work by inhibiting blood vessel growth in tumors, R-DXd is an antibody-drug conjugate that delivers a potent chemotherapy agent directly to cancer cells. This targeted delivery system aims to increase the treatment's effectiveness while potentially minimizing side effects. Additionally, the combination of R-DXd with or without bevacizumab provides flexibility in treatment strategies, which could improve outcomes for patients with different needs.

Research has shown that Raludotatug Deruxtecan (R-DXd) holds promise for treating ovarian cancer. In this trial, one group of participants will receive R-DXd with or without bevacizumab. Studies have found that R-DXd is generally safe and well-tolerated in patients with advanced ovarian cancer. It targets specific proteins on cancer cells to halt their growth. Early results suggest this treatment could be crucial for patients whose cancer does not respond to standard treatments. Additionally, R-DXd may benefit those with cancers that express a protein called CDH6.⁶⁷⁸⁹¹⁰